Register Now

Late-Breaking Clinical Trials

Late-Breaking Clinical Trials

Late-Breaking Clinical Trials

First-in-Human Evidence. Real-World Dialogue. Immediate Impact.

Late-Breaking Clinical Trials (LBCT) debut at HRX Live 2026 as an inaugural program.

Presentations will spotlight First-in-Human studies at the moment they begin to influence thinking, discussion, and decision-making across electrophysiology and cardiovascular innovation.

Where New Evidence Meets Real-World Decision-Making

Presented live on the HRX Main Stage, the inaugural LBCT session will bring early clinical evidence into a collaborative, cross-disciplinary environment, connecting emerging data with the clinicians, researchers, industry leaders, and innovators shaping what comes next.

LBCT presentations will be focused on First-in-Human studies, including new data not previously presented at any another conference.

Accelerate Understanding What New Data Means — Now

Late-Breaking Clinical Trials at HRX Live are designed to:

  • Surface new and emerging clinical data, including First-in-Human experience
  • Connect evidence to real-world workflows, adoption, and implementation
  • Bring clinicians, industry, startups, and regulators into the same conversation

LBCT Submissions Open June 2026

Presenting Late Breaking Clinical Trials at HRX Live offers a unique opportunity to:

  • Share early clinical evidence in a high-trust, collaborative setting

  • Engage directly with clinicians, industry leaders, and innovators

  • Receive real-time feedback and perspective beyond traditional scientific formats

  • Participate in conversations that influence adoption, integration, and next-step development

Only a select number of submissions will be chosen for Main Stage presentation. Additional submission details and guidelines will be published closer to the opening date.

The submission period is now closed and will open in June 2026. Stay tuned!

Frequently Asked Questions (FAQs)